"If you were to look at this paper and others that are coming out like it, it appears that disposable cystoscopy is going to be the future for us," said David D. Thiel, MD.
In this interview, David D. Thiel, MD, discusses take-home messages from his study, “Conversion to Disposable Cystoscopes Decreased Post-procedure Encounters and Infections Compared to Reusable Cystoscopes.” Thiel is the chief of clinical practice at Mayo Clinic in Jacksonville, Florida.
Video Transcript:
The take-home message for this paper right now, in my opinion, is that disposable cystoscopes may be the future for us in office-based practice in that number 1, it looks like it may lead to less engagement of the healthcare system following the procedure. Number 2, it looks like it may lead to less infections compared to reusable scopes. And number 3, it eliminates the need for instrument reprocessing at your office. So, if you were to look at this paper and others that are coming out like it, it appears that disposable cystoscopy is going to be the future for us.
This transcription has been edited for clarity.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.